Neurizon Therapeutics Limited (ASX:NUZ)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Corporate & Research	17.59M	1.54M	841.71K	950.39K	834.70K
Pharmaceutical - Epichem	-	-	-	3.11M	3.76M
Inter-Segment Elimination	-	-	-	-163.51K	-82.03K
Total	17.59M	1.54M	841.71K	3.90M	4.51M

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018	Jun 30, 2017
Switzerland	17.28K	1.04M
Australia	2.69M	1.74M
USA	100.44K	181.70K
Others	18.76K	96.09K
Sweden	-	323.85K
Total	2.82M	3.38M

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 30, 2026

Data Sources Report a data error